

IMPLANET announces the success of its capital increase

- Fundraising of €4.49 million through the issuance of 17,942,989 new shares
- Enabling the acceleration of its strategic deployment and extending financial visibility to more than 12 months

Bordeaux, Boston, November 3, 2025 – 08:00 am CEST - IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME) (the “**Company**”), a medical technology company specializing in vertebral implants for orthopedic surgery and the distribution of advanced medical equipment, today announced the successful completion of its cash capital increase with preferential subscription rights (“**PSRs**”), as announced on October 9, 2025 (the “**Capital Increase**”). This transaction enabled the Company to raise a total of €4.49 million through the issuance of 17,942,989 new shares (the “**New Shares**”) at a subscription price of €0.25 per share, representing a 29.2% discount compared with IMPLANET’s closing share price on October 8, 2025 (€0.353), the date on which the issue price was set by the Board of Directors.

Ludovic Lastennet, IMPLANET’s Chief Executive Officer, stated: *"I would like to sincerely thank our shareholders, guarantors, and the management team of our key partner Sanyou Medical for their trust and commitment. The success of this capital increase marks a decisive milestone in the implementation of our development strategy and significantly strengthens IMPLANET’s financial resources, enabling us to pursue our roadmap with renewed ambition."*

Use of Proceeds

The net proceeds from the Capital Increase, amounting to €4.49 million, will enable the Company, in accordance with the press release dated October 8, 2025, to:

- Strengthen the Company’s presence in the United States:
 - Reinforce the resources and commercial capabilities available to the historical team through the recruitment of an experienced sales force;
 - Equip the Company with the necessary tools to accelerate the rollout of JAZZ® and the co-developed products with Sanyou Medical;
 - Strengthen the Company’s direct approach by expanding its scientific team of key opinion leaders.
- Deploy co-developed products in strategic geographic regions:
 - Support the commercial rollout of JSS and other Sanyou product ranges in France, the United States, and internationally.
- Strengthen market momentum and product offering:
 - Position Implanet as the exclusive distributor in Europe and the United States for the Sanyou Medical group’s assistance technologies and those of its partners;
 - Launch the SMTP Quntas range (ultrasonic scalpels with aspiration), marking the brand’s entry into the revision and tumor surgery markets.
- Finalize the registration of existing products under the European Medical Device Regulation (MDR) and to obtain FDA 510(k) clearances.

This capital increase provides financial visibility for more than 12 months.

Results of the Capital Increase with Preferential Subscription Rights (PSRs)

The Capital Increase generated total demand for 17,942,989 New Shares at a subscription price of €0.25 per share, on the basis of 1 New Share for every 7 existing shares held, representing a total requested amount of €4,485,747.25, equivalent to 100.00% of the initial offering amount (€4,485,747.25).

The subscriptions were allocated as follows:

- 10,879,182 New Shares on an irreducible basis, representing 60.63% of the New Shares issued;
- 1,972,988 New Shares on a reducible basis, representing 11.00% of the New Shares issued;
- 942,742 New Shares on a free basis, representing 5.25% of the New Shares issued;
- 4,148,077 New Shares, or 23.12% of the total, were allocated to the Guarantors, distributed as follows:

Guarantors	New Shares
Nice&Green	662,024
Friedland Gestion	660,698
Maitice Gestion	660,698
Gestys	817,180
Treecap B.V.	391,203
Vesta Capital	956,274
Total	4,148,077

The allocation rate for irreducible and reducible subscriptions amounts to 71.63%.

The allocation rate for free subscriptions amounts to 5.25%.

It is recalled that all Guarantors received a commission equal to 10% of the amount of their respective commitments, regardless of the number of shares ultimately allocated to them.

Finally, in accordance with the subscription commitments signed on September 26 and 28, 2025, certain corporate officers of IMPLANET and Shanghai Sanyou Medical Co., Ltd., who did not hold any shares in the Company as of that date, subscribed to the Capital Increase for a total amount of €2,099,985, representing 46.81% of the Capital Increase.

Settlement and Delivery of the New Shares

Following settlement and delivery, scheduled for November 5, 2025, IMPLANET's share capital will amount to €1,435,439.18, divided into 143,543,918 shares with a par value of €0.01 each.

The New Shares will be admitted to trading on Euronext Growth Paris on the same day, on the same trading line as the existing shares (ISIN code: FR0013470168 – Ticker: ALIMP).

Impact of the Capital Increase on the Shareholding Structure

The table below presents the breakdown of share capital after completion of the Capital Increase:

	after completion of the Capital Increase	
	Number of Shares	% of Share Capital and Voting Rights (undiluted basis)
Sanyou (HK) International Medical Holding CO Limited	93,176,946	64.91%
Sanyou Corporate Officers	8,399,940	5.85%
Total Sanyou concerted group	101,576,886	70.76%
Guarantors	4,148,077	2.89%
Management and employees	1,486,696	1.04%
Other individual shareholders	602,555	0.42%
Free float	35,729,704	24.89%
Total	143,543,918	100.00%

Impact of the Capital Increase on Shareholders' Situation

The impact of the Capital Increase on the share of consolidated equity per share (calculations based on consolidated equity attributable to the Group as reported in the interim financial statements as of June 30, 2025, excluding interim losses, and on a total of 125,600,929 shares comprising the Company's share capital prior to the completion of the Capital Increase) is as follows:

Share of Consolidated Equity per Share (in euros)		
	Undiluted Base*	Fully Diluted Base (assuming exercise of all existing instruments**)
Before issuance of the New Shares under the Capital Increase	-0.011	0.000
Après émission de 17942.989 Actions Nouvelles provenant de l'Augmentation de Capital	0.022	0.031

*: The amount of consolidated equity as of June 30, 2025, adjusted for capital increases completed between July 1, 2025 and the date hereof and excluding interim losses, amounts to –€1,358 thousand.

**: Assuming the exercise of all outstanding share warrants (BSA), founder share warrants (BSPCE), and stock options, whether exercisable or not, i.e., 1,375,354 BSPCE, 522,500 stock options, 990,000 BSA, and 728,805 free shares, the exercise of which would result in the creation of 1,971,235 new shares.

The holding of a shareholder who owned 1% of the Company's share capital prior to the Capital Increase and who did not participate in the transaction would be as follows:

Shareholder's Ownership (%)		
	Undiluted Base	Fully Diluted Base (assuming exercise of all existing instruments**)
Before issuance of the New Shares under the Capital Increase	1.000	0.985
After issuance of 17,942,989 New Shares under the Capital Increase	0.875	0.863

**: Assuming the exercise of all outstanding share warrants (BSA), founder share warrants (BSPCE), and stock options, whether exercisable or not, i.e., 1,375,354 BSPCE, 522,500 stock options, 990,000 BSA, and 728,805 free shares, the exercise of which would result in the creation of 1,971,235 new shares.

Reminder of Other Terms and Conditions of the Capital Increase

Pursuant to the provisions of Articles L.411-2-1, 1° of the French Monetary and Financial Code and Article 211-2 of the General Regulations of the French Financial Markets Authority (Autorité des Marchés Financiers – AMF), this issuance did not give rise to a Prospectus approved by the AMF, as the total offering amount is below €8,000,000, it being specified that no similar offering has been made by the Company during the past twelve months.

A notice to shareholders relating to this transaction was published on October 10, 2025, in the Bulletin des Annonces Légales et Obligatoires (BALO).

Resumption of Rights to the Allocation of Company Shares

The rights of holders of stock subscription options, founder share warrants (BSPCE), and share warrants (BSA) granted or issued by the Company, which had been suspended by decision of the Board of Directors as from October 2, 2025 (00:01 a.m., Paris time) until the settlement and delivery date of the New Shares (inclusive), will resume as of the settlement and delivery date of the New Shares, i.e., on November 5, 2025 (11:59 p.m., Paris time).

The rights of holders of stock subscription options, BSPCEs, and BSAs who did not exercise their right to receive Company shares before October 2, 2025 (00:00 a.m., Paris time) will be preserved in accordance with applicable legal and regulatory provisions.

Risk Factors

The Company draws attention to the other risk factors relating to the Company and its business, which are described in Chapter 4 “Risk Factors” of the Company’s 2017 Registration Document filed with the AMF on April 16, 2018, under number D.18-0337, as well as in the annual financial report as of December 31, 2024, and the interim financial report as of June 30, 2025.

The main additional risk factors relating to the forthcoming Capital Increase are as follows:

- The market for the preferential subscription rights (PSRs) may offer limited liquidity and be subject to high volatility;
- Shareholders who do not exercise their PSRs will see their ownership in the Company diluted. The potential exercise of the Extension Clause could result in additional dilution;
- The market price of the Company’s shares could fluctuate and fall below the subscription price of the shares issued upon exercise of the PSRs;
- In the event of a decline in the market price of the Company’s shares, the PSRs may lose their value;
- The volatility and liquidity of the Company’s shares could fluctuate significantly;
- Sales of the Company’s shares on the market could occur and have an adverse impact on the Company’s share price;
- Shareholders may experience significant dilution as a result of future capital increases.

Advisors to the Transaction

Atout Capital

Financial Advisor

Bird & Bird

Legal Advisor

Upcoming Financial Events

- **Full-year 2025 revenue**, January 13, 2026, after market close

About IMPLANET

IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery and distributes medical technology equipment. Its activities focus on an innovative solution to improve the treatment of spinal pathologies (JAZZ®), complemented by the product range of thoraco-lumbar screws, cages, and cervical plates, acquired through Orthopaedic & Spine Development (OSD) in May 2021. In 2022, the Company entered into a commercial, technological, and financial partnership with Sanyou Medical, China's second-largest medical device manufacturer. As part of this strategic agreement, IMPLANET developed in 2024 the Jazz Spinal System™ hybrid fixation system, a unique new range featuring a comprehensive pedicle screw solution, combined with the market's most advanced braided implant technology, JAZZ®. IMPLANET's orthopedic platform is built on the traceability of its products. Protected by four families of international patents, JAZZ® has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA), CE marking in Europe, and ANVISA approval in Brazil. IMPLANET employs 43 people and generated €9.4 million in consolidated revenue in 2024. Based near Bordeaux, France, IMPLANET has operated a U.S. subsidiary in Boston since 2013. IMPLANET is listed on the Euronext Growth market in Paris.

For more information, visit www.Implanet.com.

Contacts

IMPLANET

Ludovic Lastennet, CEO
David Dieumegard, CFO
Tel. : 05 57 99 55 55
investors@implanet.com

NEWCAP

Investor Relations
Mathilde Bohin
Tel. : 01 44 71 94 94
implanet@newcap.eu

NEWCAP

Media Relations
Arthur Rouillé
Tel. : 01 44 71 94 94
implanet@newcap.eu

Disclaimer

This press release contains forward-looking statements relating to IMPLANET and its business activities. IMPLANET believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the forecasts expressed in these forward-looking statements will be achieved, as they are subject to various risks and uncertainties, including those described in IMPLANET's Reference Document filed with the French Financial Markets Authority (Autorité des Marchés Financiers - AMF) on April 16, 2018, under number D.18-0337, as well as in the annual financial report as of December 31, 2024, and the interim financial report as of June 30, 2025, available on the Company's website (www.Implanet-invest.com). These forward-looking statements are also subject to risks unknown to IMPLANET or risks that IMPLANET does not currently consider material. The realization of some or all of these risks could cause the actual results, financial conditions, performance, or achievements of IMPLANET to differ materially from those expressed in these forward-looking statements. IMPLANET undertakes no obligation to update the information or forward-looking statements contained herein, except as required under applicable regulations, including Articles 223-1 et seq. of the General Regulation of the AMF.

This press release does not constitute an offer to sell or a solicitation of an offer to purchase any securities, and there will be no sale of ordinary shares in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or approval under the securities laws of such jurisdiction.

The distribution of this press release may be subject to specific legal or regulatory restrictions in certain countries. Persons in possession of this document are required to inform themselves about and comply with any such local restrictions.

This press release constitutes a promotional communication and not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017 (as amended, the "Prospectus Regulation").

With respect to the Member States of the European Economic Area (other than France) (the "Member States"), no action has been or will be taken to permit a public offering of securities requiring the publication of a prospectus in any of these Member States. Consequently, the securities may not and will not be offered in any of these Member States (other than France) except in accordance with the exemptions provided for in Article 1(4) of the Prospectus Regulation, or in other cases not requiring IMPLANET to publish a prospectus under the Prospectus Regulation and/or applicable local regulations. This press release does not constitute a public offering of securities in the United Kingdom.

This press release may not be published, distributed, or disseminated in the United States (including its territories and possessions). It does not constitute an offer or solicitation to purchase, sell, or subscribe for securities in the United States. The securities mentioned herein have not been registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any

state or other securities laws in the United States, and may not be offered or sold in the United States absent registration under the Securities Act or pursuant to an applicable exemption therefrom. IMPLANET does not intend to register any portion of the offering in the United States under the Securities Act, nor to conduct a public offering in the United States.

This press release may not be distributed, directly or indirectly, in or into the United States, Canada, Australia, or Japan.

Finally, this press release may be drafted in both French and English. In the event of any differences between the two versions, the French version shall prevail.